MAR 18 2027
Alexion, AstraZeneca Rare Disease — efzimfotase alfa $AZN
for hypophosphatasia (HPP) in patients aged 2 years and older
Accepted SEP 18 2026.
Drug Watch — recent news on efzimfotase alfa
- Efzimfotase alfa granted Priority Review in the US as treatment for patients with hypophosphatasia aged 2 years and older - astrazeneca.com
- FDA grants priority review to efzimfotase alfa for hypophosphatasia in patients aged 2 years and older - Contemporary Pediatrics
- Efzimfotase alfa granted Priority Review in the US as treatment for patients with hypophosphatasia aged 2 years and older - astrazeneca.com
- AstraZeneca hails US priority review designation for efzimfotase alfa - London South East
- AstraZeneca’s BLA for efzimfotase alfa accepted, granted Priority Review by FDA - TipRanks